Tags

Type your tag names separated by a space and hit enter

Methotrexate for inflammatory bowel disease: time for reconsideration.
Expert Rev Gastroenterol Hepatol. 2019 05; 13(5):407-409.ER

Authors+Show Affiliations

a Department of Gastroenterology, Herlev Hospital , University of Copenhagen , Herlev , Denmark.b Department of Gastroenterology & Hepatology , Odense University Hospital , Odense , Denmark.a Department of Gastroenterology, Herlev Hospital , University of Copenhagen , Herlev , Denmark.

Pub Type(s)

Editorial

Language

eng

PubMed ID

30895827

Citation

Nielsen, Ole Haagen, et al. "Methotrexate for Inflammatory Bowel Disease: Time for Reconsideration." Expert Review of Gastroenterology & Hepatology, vol. 13, no. 5, 2019, pp. 407-409.
Nielsen OH, Ainsworth MA, Steenholdt C. Methotrexate for inflammatory bowel disease: time for reconsideration. Expert Rev Gastroenterol Hepatol. 2019;13(5):407-409.
Nielsen, O. H., Ainsworth, M. A., & Steenholdt, C. (2019). Methotrexate for inflammatory bowel disease: time for reconsideration. Expert Review of Gastroenterology & Hepatology, 13(5), 407-409. https://doi.org/10.1080/17474124.2019.1596797
Nielsen OH, Ainsworth MA, Steenholdt C. Methotrexate for Inflammatory Bowel Disease: Time for Reconsideration. Expert Rev Gastroenterol Hepatol. 2019;13(5):407-409. PubMed PMID: 30895827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Methotrexate for inflammatory bowel disease: time for reconsideration. AU - Nielsen,Ole Haagen, AU - Ainsworth,Mark Andrew, AU - Steenholdt,Casper, Y1 - 2019/03/21/ PY - 2019/3/22/pubmed PY - 2019/3/22/medline PY - 2019/3/22/entrez KW - Crohn’s disease KW - biologics KW - inflammatory bowel disease KW - methotrexate KW - therapy KW - ulcerative colitis SP - 407 EP - 409 JF - Expert review of gastroenterology & hepatology JO - Expert Rev Gastroenterol Hepatol VL - 13 IS - 5 SN - 1747-4132 UR - https://www.unboundmedicine.com/medline/citation/30895827/Methotrexate_for_inflammatory_bowel_disease:_time_for_reconsideration_ L2 - http://www.tandfonline.com/doi/full/10.1080/17474124.2019.1596797 DB - PRIME DP - Unbound Medicine ER -